Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil palmitil - Insmed

Drug Profile

Treprostinil palmitil - Insmed

Alternative Names: C16-TR; INS-1009; Nebulised treprostinil palmitil - Insmed; Nebulised treprostinil prodrug - Insmed; TPIP; TPIS - Insmed; Treprostinil palmitil inhalation powder - Insmed; Treprostinil palmitil inhalation suspension - Insmed

Latest Information Update: 01 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 31 Dec 2023 Insmed has patent protection for treprostinil palmitil in USA
  • 30 Nov 2023 Insmed completes enrolment in its phase II trial for Pulmonary hypertension in Argentina, Belgium, Italy, Germany, Puerto Rico, Spain and in the US, UK, Australia, New Zealand (Inhalation, Powder) (NCT05176951)
  • 26 Oct 2023 Adverse events data from a phase II trial in Pulmonary hypertension released by Insmed
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top